Navigation Links
Vermillion Announces Receipt of NASDAQ Panel Decision
Date:9/25/2008

FREMONT, Calif., Sept. 25 /PRNewswire-FirstCall/ -- Vermillion, Inc. (Nasdaq: VRML), a molecular diagnostics company, today announced that it has received notification from The NASDAQ Stock Market LLC that the NASDAQ Listing Qualifications Panel has determined to delist the Company's securities from The NASDAQ Capital Market, effective as of the open of business on Thursday, September 25, 2008. The delisting is the result of the Company's noncompliance with the minimum stockholders' equity requirement for continued listing on The NASDAQ Capital Market, as set forth in Marketplace Rule 4310(c)(3).

The Company has been advised that its securities are immediately eligible for quotation in the Pink Sheets, an electronic quotation service for securities traded over-the-counter, effective as of the open of business on Thursday, September 25, 2008. The Company's shares will continue to trade under the symbol VRML. In addition, the Company has been advised that a Market Maker is filing the necessary application with the Financial Industry Regulatory Authority ("FINRA") to quote the securities and as a result we anticipate in the near future that the Company will be quoted on the Over-the-Counter Bulletin Board (the "OTCBB").

About Vermillion

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Vermillion is based in Fremont, California. Additional information about Vermillion can be found on the Web at

SOURCE Vermillion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vermillion and Stanford Scientists Receive Best Research Award From the PAD Coalition
2. Vermillion Retains ThinkPanmure to Assist in the Evaluation of Potential Strategic Alternatives
3. Vermillion to Host Live Roundtable Discussion With Principal Investigator of OVA1(TM) Submission
4. Vermillion Announces First Quarter 2008 Financial Results and Business Progress
5. Vermillions Roundtable Teleconference Highlights Peripheral Artery Disease Diagnostic Program; Features Commentary from Vascular Medicine Expert
6. Vermillion Announces Appointment of John Hamilton to Board of Directors
7. Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Artery Disease
8. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
9. Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones
10. Vermillion Announces Effectiveness of Reverse Stock Split
11. Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014 Over the last decade, the ... rising R&D budgets and increased acceptance of new filtration ... and biotechnology industries are also catalyzing the growth of ... is expected to grow at a strong CAGR during ... be worth $2,532.6 million by 2019. The market is ...
(Date:9/30/2014)... 30, 2014 Follow us on ... each type of cholesterol carrier or lipoprotein in the ... excessive cholesterol levels in the body, especially along the ... heart attack and other cardiovascular disorders. Cardiovascular Diseases (CVD) ... for cholesterol levels on a regular basis, to assess ...
(Date:9/30/2014)... Sept. 30, 2014 CORD:USE Cord Blood Bank ... that it has entered into an Equity and Exclusive ... has licensed a series of patented technologies for the isolation ... clinical applications.  Tianhe is performing Phase I/II clinical trials ... Spain using Tianhe,s Stem Cell Educator Therapy ...
(Date:9/30/2014)... Genedata, a leading provider ... and related life science research, today announced ... Selector as its host-pathogen data analysis platform ... a European consortium dedicated to improving the ... anti-fungal drug therapies. Genedata Selector supports this ...
Breaking Biology Technology:Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 4Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 5Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 3Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 4CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 4FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3
... Gore PharmBIO Products Launches Unique Online Configurator For the ... ... 24 Gore PharmBIO Products has,launched an industry first -- ... and configuring fluid,assemblies for biopharmaceutical manufacturers., The GORE(TM) STA-PURE(SM) ...
... NEOG ) announced today that its revenues for ... increased 26% from the previous year,s first,quarter to $28,805,000. ... $3,011,000 to $3,733,000, or to $0.25 per share in ... Neogen,s first quarter revenues, net income, and earnings per ...
... to new screening platform for antibody therapeutics, ... ROG),announced today that it has completed the acquisition ... warrants of ARIUS Research (TSX: ARI). On,September 19th, ... of,Arrangement previously approved by the security holders and ...
Cached Biology Technology:Gore's Legacy of Innovation Extends From Products to Processes 2Gore's Legacy of Innovation Extends From Products to Processes 3Neogen Reports 26% Increase in Revenues 2Neogen Reports 26% Increase in Revenues 3Neogen Reports 26% Increase in Revenues 4Neogen Reports 26% Increase in Revenues 5Neogen Reports 26% Increase in Revenues 6Roche completes acquisition of ARIUS 2
(Date:9/30/2014)... professor and Howard Hughes Medical Institute investigator, and ... recipients in the 2014 round of grants from ... BRAIN (Brain Research through Advancing Innovative Neurotechnologies) Initiative ... September 30, provides more than $3 million in ... , The BRAIN Initiative, launched last year, is ...
(Date:9/30/2014)... news release is available in German . ... are among the most expensive foods in the world. Because ... find them. But the distinctive smell of truffles is not ... French scientists under the direction of the Goethe University Frankfurt ... produced by soil bacteria which are trapped inside truffle fruiting ...
(Date:9/30/2014)... Here,s some hope: A new research report published in ... , explains how scientists developed a synthetic version ... embryo development in human and mouse eggs similar to ... cell during fertilization. , "We believe that the results ... our understanding of human fertilization by providing a precise ...
Breaking Biology News(10 mins):Salk scientists receive $3 million for BRAIN Initiative grant 2On the trail of the truffle flavor 2Synthetic sperm protein raises the chance for successful in vitro fertilization 2
... the Universitat Autònoma de Barcelona has developed new miniature ... size and thickness as a fingernail and reduce the ... or a few hours, depending on each chain. These ... from paternity tests and identifying people to detecting genetically ...
... Roundup® is widely used to eradicate weeds. But a ... finds that the chemical may be eradicating much more ... Relyea found that Roundup®, the second most commonly applied ... amphibians. This field experiment is one of the most ...
... of mouse actually shrink during the winter, causing the mice ... new study found. , The results showed that, during the ... ?the mental map that helps them remember important places in ... to show seasonal changes in the structure and the functioning ...
Cached Biology News:New miniaturised chip dramatically reduces time taken for DNA analysis 2New miniaturised chip dramatically reduces time taken for DNA analysis 3Roundup®highly lethal to amphibians, finds University of Pittsburgh researcher 2Mice brains shrink during winter, impairing some learning and memory 2Mice brains shrink during winter, impairing some learning and memory 3
Antibody specific for histone H3 acetylated at any of the five N-terminal lysine residues. Rabbit polyclonal serum. Antigen: Synthetic peptide derived from histone H3 N-terminal region, mulitpliy...
The FailSafe™ PROBES Real-Time PCR System enables rapid, precise optimization of PCR experiments in which the product is detected using fluorescent target-specific labeled probes....
NuParaffin Kit Application: Flow Cytometry Reactivity: Human...
Immunofixation Gel Kit, requires IF100 Reactivity: Human Applications: Immunofixation ...
Biology Products: